1. Market Research
  2. > NeuroSearch A/S – Product Pipeline Review – 2013

NeuroSearch A/S – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 48 pages

NeuroSearch A/S – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “NeuroSearch A/S - Product Pipeline Review - 2013” provides data on the NeuroSearch A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, NeuroSearch A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from NeuroSearch A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NeuroSearch A/S - Brief NeuroSearch A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NeuroSearch A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NeuroSearch A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NeuroSearch A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NeuroSearch A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NeuroSearch A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NeuroSearch A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NeuroSearch A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NeuroSearch A/S and identify potential opportunities in those areas.

Table Of Contents

NeuroSearch A/S - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
NeuroSearch A/S Snapshot 5
NeuroSearch A/S Overview 5
Key Information 5
Key Facts 5
NeuroSearch A/S - Research and Development Overview 6
Key Therapeutic Areas 6
NeuroSearch A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
NeuroSearch A/S - Pipeline Products Glance 10
NeuroSearch A/S - Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
NeuroSearch A/S Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
NeuroSearch A/S - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
NeuroSearch A/S - Drug Profiles 14
NS-11394 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ordopidine 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
seridopidine 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
tesofensine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
NeuroSearch A/S - Pipeline Products by Route of Administration 19
NeuroSearch A/S - Pipeline Products By Mechanism of Action 20
NeuroSearch A/S - Recent Pipeline Updates 21
NeuroSearch A/S - Dormant Projects 22
NeuroSearch A/S - Discontinued Pipeline Products 23
Discontinued Pipeline Product Profiles 23
tesofensine 23
NS-2710 23
NeuroSearch A/S - Company Statement 24
NeuroSearch A/S - Locations And Subsidiaries 26
Head Office 26
Other Locations and Subsidiaries 26
Financial Deals Landscape 27
NeuroSearch A/S, Deals Summary 27
NeuroSearch A/S, Pharmaceuticals and Healthcare, Deal Details 28
Venture Financing 28
ZGene Secures $2.4 Million In Series D Financing 28
Partnerships 30
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 30
NeuroSearch Enters Into Co-Development Agreement With Janssen Pharmaceutica 31
NeuroSearch Enters Into Drug Discovery Agreement With Eli Lilly 33
NeuroSearch Expands Its Agreement With GlaxoSmithKline 35
Equity Offering 36
NeuroSearch Completes Rights Offering Of $86 Million 36
NeuroSearch Completes Private Placement Of $17.6 Million 38
NeuroSearch Completes Rights Offering For $149 Million 40
Asset Transactions 42
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For $26 Million 42
Acquisition 44
Biolin Scientific Acquires Sophion Bioscience 44
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48



List of Tables

NeuroSearch A/S, Key Information 5
NeuroSearch A/S, Key Facts 5
NeuroSearch A/S - Pipeline by Indication, 2013 7
NeuroSearch A/S - Pipeline by Stage of Development, 2013 8
NeuroSearch A/S - Monotherapy Products in Pipeline, 2013 9
NeuroSearch A/S - Phase III, 2013 10
NeuroSearch A/S - Phase II, 2013 11
NeuroSearch A/S - Phase I, 2013 12
NeuroSearch A/S - Pre-Clinical, 2013 13
NeuroSearch A/S - Pipeline By Route of Administration, 2013 19
NeuroSearch A/S - Pipeline Products By Mechanism of Action, 2013 20
NeuroSearch A/S - Recent Pipeline Updates, 2013 21
NeuroSearch A/S - Dormant Developmental Projects,2013 22
NeuroSearch A/S - Discontinued Pipeline Products, 2013 23
NeuroSearch A/S, Subsidiaries 26
NeuroSearch A/S, Deals Summary 27
ZGene Secures $2.4 Million In Series D Financing 28
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 30
NeuroSearch Enters Into Co-Development Agreement With Janssen Pharmaceutica 31
NeuroSearch Enters Into Drug Discovery Agreement With Eli Lilly 33
NeuroSearch Expands Its Agreement With GlaxoSmithKline 35
NeuroSearch Completes Rights Offering Of $86 Million 36
NeuroSearch Completes Private Placement Of $17.6 Million 38
NeuroSearch Completes Rights Offering For $149 Million 40
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For $26 Million 42
Biolin Scientific Acquires Sophion Bioscience 44



List of Figures

NeuroSearch A/S - Pipeline by Indication, 2013 7
NeuroSearch A/S - Pipeline by Stage of Development, 2013 8
NeuroSearch A/S - Monotherapy Products in Pipeline, 2013 9
NeuroSearch A/S - Pipeline By Route of Administration, 2013 19
NeuroSearch A/S - Pipeline Products By Mechanism of Action, 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.